A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Diphenhydramine; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Paracetamol; Prednisone
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms LUNAR
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results (n=70) assessing the relationship between parameters of B-cell depletion and measures of renal response, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results (n=522) assessing the predictive value of early measurements of the level of proteinuria and to identify proteinuria cutoffs that best identify patients who will achieve CRR at 18 months from LUNAR and BELONG trials presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top